Precigen, Inc. (NASDAQ:PGEN - Get Free Report) Director Jeffrey Kindler sold 185,000 shares of the company's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the sale, the director directly owned 17,100 shares in the company, valued at $127,224. This represents a 91.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Precigen Price Performance
Shares of NASDAQ PGEN opened at $6.95 on Friday. Precigen, Inc. has a fifty-two week low of $2.99 and a fifty-two week high of $7.72. The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.89 and a current ratio of 4.58. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -6.68 and a beta of 1.02. The company has a 50 day simple moving average of $6.05 and a two-hundred day simple moving average of $4.75.
Precigen (NASDAQ:PGEN - Get Free Report) last released its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.06. The business had revenue of $54.98 million for the quarter, compared to the consensus estimate of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.Precigen's revenue for the quarter was up 6322.7% compared to the same quarter last year. Analysts expect that Precigen, Inc. will post 0.25 EPS for the current fiscal year.
Hedge Funds Weigh In On Precigen
Several large investors have recently added to or reduced their stakes in the company. Xponance LLC boosted its position in shares of Precigen by 21.3% in the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 2,496 shares during the period. BNP Paribas Financial Markets raised its stake in Precigen by 6.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company's stock valued at $170,000 after purchasing an additional 2,993 shares during the period. Composition Wealth LLC boosted its position in shares of Precigen by 16.5% during the fourth quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company's stock worth $89,000 after acquiring an additional 3,000 shares during the last quarter. Intech Investment Management LLC raised its stake in Precigen by 5.2% during the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company's stock valued at $263,000 after purchasing an additional 3,137 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in Precigen by 0.9% during the first quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company's stock valued at $1,449,000 after purchasing an additional 3,250 shares during the last quarter. Hedge funds and other institutional investors own 33.51% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the stock. HC Wainwright boosted their price objective on shares of Precigen from $14.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Wall Street Zen upgraded shares of Precigen from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Zacks Research raised shares of Precigen from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 5th. Citizens Jmp raised their target price on Precigen from $9.00 to $11.00 and gave the stock a "market outperform" rating in a report on Thursday, May 14th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Precigen in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $14.50.
View Our Latest Report on Precigen
About Precigen
(
Get Free Report)
Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.
The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
